Navigation Links
Reproductive Medicine Associates of New York Now Participating in the WINFertility® Direct-to-Consumer IVF Program
Date:2/5/2013

White Plains NY and NY, NY (PRWEB) February 05, 2013

WINFertility, Inc., a leader in Infertility Management Programs for insurers and employers, announced the extension of its consumer offering throughout the metropolitan New York area with the addition of Reproductive Medicine Associates of New York (“RMA of NY”). This marks the 32nd location where consumers can access The WINFertility Program. The expansion increases the availability of high quality, affordable fertility care for many of the over five million NY Tri-State residents facing infertility today who are without advanced infertility insurance coverage.

WINFertility simplifies, streamlines and discounts fertility treatments for uninsured patients trying to conceive. State-of-the-art, evidence-based treatment programs for IUI, IVF and Third Party Reproduction are delivered by WINFertility’s highly accredited network of fertility specialists. Infertility medications are included in the single-cycle discounted price, and there is no age or medical criteria required to enroll in the program. If treatment is indicated by a participating provider and the patient has no infertility insurance coverage or has exhausted her benefits, she is then eligible to enroll in the WINFertility Program.

WINFertility’s FertilityCoach Nurses(SM) are available on a 24/7 basis for education and care coordination, supported by a Medical Advisory Board comprised of industry-leading Reproductive Endocrinologists. Financing programs that provide preferred rates are also available to WINFertility patients.

The WINFertility Treatment Program is now available at Reproductive Medicine Associates of New York (RMANY), one of the largest and most successful fertility practices in the country with five convenient offices located in Manhattan, Brooklyn, Garden City, White Plains and Cornwall, NY.

“RMA of NY was founded with the goal of helping to create families. By combining medical expertise and compassionate treatment of each and every patient and couple, we have set the standard for patient-friendly care. Our treatment innovations, research efforts and excellent success rates are evidence of our commitment to the medical experience, while our highly-trained staff of caring professionals provides individual attention and expertise” said Dr. Alan Copperman, Director and Founding Partner. “By teaming with WINFertility, we are providing patients with access to savings on treatment and medication packages and reducing barriers to parenthood by lessening their emotional and financial stress.”

More Access for More Patients

“The Tri-State area has over 32 million people who call it home. We are excited to be able to offer our unique program across a wide expanse of one of the country’s largest and most dynamic marketplaces, where so many struggle with infertility and its associated expenses,” commented Tom Boyajy, COO of WINFertility. “The WINFertility approach is to promote high quality infertility care at a competitive cost. By affiliating with one of the most admired fertility programs in the country, we are confident that WINFertility patients will be the recipients of both compassionate, patient-centered care and excellent clinical results. Coupled with WINFertility’s proprietary, bundled packages, fertility management expertise, and considerable buying power, we are confident that metropolitan NY residents will receive the very best IVF treatment value possible.”

About WINFertility

Founded in 2000, WINFertility is the national leader in Infertility Management Programs, annually managing infertility treatment for many thousands of infertility patients for major insurers and employers. WINFertility has leveraged their decade-long experience and clinical results in the fertility field, direct contracts with fellowship-trained fertility specialists, pharmaceutical manufacturers and national specialty pharmacies, to offer this unique direct-to-consumer program. Now, patients without infertility insurance coverage in twenty-two states can take advantage of WINFertility’s integrated platform to access evidence-based protocols, high-quality providers and discounts enjoyed only by the largest healthcare purchasers. For more information, visit us at http://www.winfertility.com.

About Reproductive Medicine Associates of New York

Reproductive Medicine Associates of New York (RMA of New York) is widely recognized as a national and international leader in state-of-the-art reproductive medicine. Led by an integrated team of doctors and scientists with extensive reproductive endocrinology, fertility and urology experience and training, RMA of New York consistently reports success rates to the Society for Assisted Reproductive Technology (SART) and the Center for Disease Control and Prevention (CDC) and is internationally recognized for achieving high success rates in their treatment of infertility. RMA of New York maximizes access to care by helping patients explore all insurance coverage and financing options available for treatment. Headquartered in midtown Manhattan, RMA of New York has patient care facilities in Garden City, White Plains, Brooklyn and Cornwall, NY. For more information, please visit http://www.rmany.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10376469.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
2. Future reproductive outcomes for women who have had an ectopic pregnancy
3. Researcher: Military should reassess reproductive health care for women
4. Exercise affects reproductive ability in horses
5. Reproductive Health Matters announces publication of its themed issue
6. Cervical Health Awareness Month 2013: Maternal & Family Health Services Focuses on Access to Reproductive Healthcare to Reduce Cervical Cancer
7. Adolescent sexual and reproductive health priorities identified
8. First targeted nanomedicine to enter human clinical studies
9. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
10. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
11. DNA Testing Finds Allergens, Toxins in Traditional Chinese Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology: